Abstract
Many cancer prevention strategies are unlikely to provide equal risk reduction in all subjects, but instead are predicted to be particularly useful for specific individuals. An important research challenge is to devise methods for individualization of cancer prevention recommendations, such that particular interventions are assigned to those who will gain the most. Research in this area is at an early stage, but progress that allows rational assignment of specific prevention strategies to particular individuals who will benefit would decrease the cost, minimize the toxicity, and increase the efficacy of interventions intended to prevent cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Thompson IM, Goodman PJ, Tangen CM, et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Daly M, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant Breast and Bowel Project (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256
Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D’Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P, Tamoxifen Study Group (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165
Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87: 1622–1629
Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J (2000) Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9:911–915
Atkinson C, Warren R, Bingham SA, Day NE (1999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8:863–866
Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group [see comments]. JAMA 276:1404–1408
Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women [see comments]. N Engl J Med 336: 611–617
Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292–1299
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280
Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55:3973–3975
Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R (1990) Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693–1697
Torrisi R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C, Decensi A (2000) Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 87: 601–605
Novelli G, Margiotti K, Sangiuolo F, Reichardt JK (2001) Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2:65–72
Costantino JP (2001) Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. Ann N YAcad Sci 949: 280–285
Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DJ (1997) Circulating and skeletal insulin-like growth factor-I (IGF-1) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21: 217–223
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396
Pollak M, Blouin MJ, Zhang JC, Kopchick JJ (2001) Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 85:428–430
Pollak M, Foulkes WD (2003) Challenges to cancer control by screening. Nat Rev Cancer 3:297–303
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pollak, M. (2005). Individualizing Interventions for Cancer Prevention. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics III. Recent Results in Cancer Research, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26980-0_5
Download citation
DOI: https://doi.org/10.1007/3-540-26980-0_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22228-6
Online ISBN: 978-3-540-26980-9
eBook Packages: MedicineMedicine (R0)